ATS: Tezepelumab Reduces Asthma Exacerbations Across Asthma Phenotypes

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

MONDAY, May 18, 2026 -- For patients with severe, uncontrolled asthma, tezepelumab is associated with substantial reductions in asthma exacerbations across asthma phenotypes and underrepresented populations, according to a study published online May 18 in the American Journal of Respiratory and Critical Care Medicine to coincide with the American Thoracic Society 2026 International Conference, held from May 15 to 20 in Orlando, Florida.

Njira Lugogo, M.D., from the University of Michigan in Ann Arbor, and colleagues examined the effectiveness and safety of tezepelumab in a diverse, real-world cohort of 286 U.S. patients (adults and adolescents) with severe, uncontrolled asthma that included different asthma phenotypes and underrepresented populations. Participants received 210 mg tezepelumab subcutaneously every four weeks for 52 weeks.

Of the patients enrolled, 42 percent had a blood eosinophil count ≥300 cells/µL, 58 percent had positive allergy status, 22 percent were Black/African American, 7 percent were adolescents, 20 percent had comorbid chronic obstructive pulmonary disease, and 29 percent were smokers. The researchers found that the annualized asthma exacerbation rate decreased by 70 percent overall between the baseline and treatment periods and by 54 to 77 percent across asthma phenotypes and underrepresented populations. Clinically meaningful improvements from baseline were seen in 74, 63, and 80 percent of patients in the Asthma Control Questionnaire-6, Asthma Impairment and Risk Questionnaire, and St. George's Respiratory Questionnaire scores at week 52 overall, with robust results seen across asthma phenotypes and underrepresented populations (ranges: 64 to 86, 51 to 75, and 63 to 91 percent, respectively). During the treatment period after tezepelumab initiation, 9.8 percent of patients reported a serious adverse event.

"The study results were really reassuring in terms of both safety and efficacy," Lugogo said in a statement.

The study was sponsored by AstraZeneca, the manufacturer of tezepelumab.

Abstract/Full Text

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-05-19 09:50

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords